X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (343) 343
humans (317) 317
oncology (211) 211
hematology (206) 206
male (201) 201
female (196) 196
middle aged (196) 196
aged (189) 189
adult (164) 164
abridged index medicus (142) 142
aged, 80 and over (123) 123
leukemia, lymphocytic, chronic, b-cell - drug therapy (106) 106
treatment outcome (105) 105
article (80) 80
prognosis (79) 79
rituximab (77) 77
chronic lymphocytic leukemia (74) 74
hemic and lymphatic diseases (74) 74
leukemia (71) 71
antineoplastic combined chemotherapy protocols - therapeutic use (68) 68
survival (68) 68
cancer (63) 63
cll (63) 63
leukemia, lymphocytic, chronic, b-cell - genetics (61) 61
leukemia, lymphocytic, chronic, b-cell - pathology (61) 61
disease-free survival (56) 56
antineoplastic agents - therapeutic use (54) 54
therapy (54) 54
fludarabine (49) 49
care and treatment (48) 48
hematology, oncology and palliative medicine (46) 46
adolescent (45) 45
cyclophosphamide (42) 42
chronic lymphocytic-leukemia (40) 40
expression (40) 40
initial therapy (40) 40
leukemia, lymphocytic, chronic, b-cell - mortality (39) 39
vidarabine - analogs & derivatives (39) 39
retrospective studies (37) 37
patients (36) 36
chemotherapy (35) 35
immune system diseases (35) 35
leukemia, lymphocytic, chronic, b-cell - therapy (35) 35
lymphoid neoplasia (35) 35
research (34) 34
survival rate (34) 34
young adult (34) 34
follow-up studies (33) 33
apoptosis (32) 32
chronic lymphatic leukemia (32) 32
dose-response relationship, drug (32) 32
lymphoma (32) 32
ibrutinib (31) 31
survival analysis (31) 31
recurrence (30) 30
risk factors (30) 30
alemtuzumab (29) 29
animals (29) 29
antineoplastic combined chemotherapy protocols - adverse effects (29) 29
drug administration schedule (29) 29
mutation (29) 29
patient outcomes (29) 29
acute myeloid-leukemia (28) 28
cyclophosphamide - administration & dosage (28) 28
disease progression (28) 28
kaplan-meier estimate (28) 28
leukemia, lymphocytic, chronic, b-cell - metabolism (28) 28
pyrimidines - therapeutic use (28) 28
remission induction (28) 28
antibodies, monoclonal - therapeutic use (27) 27
analysis (26) 26
drug therapy (26) 26
inhibitor (25) 25
antineoplastic agents - administration & dosage (24) 24
chronic myelogenous leukemia (24) 24
clinical trials and observations (24) 24
vidarabine - administration & dosage (24) 24
antineoplastic agents - adverse effects (23) 23
chemoimmunotherapy (23) 23
diagnosis (23) 23
drug resistance, neoplasm (23) 23
immunotherapy (23) 23
leukemia, lymphocytic, chronic, b-cell - immunology (23) 23
lymphatic leukemia (23) 23
antibodies, monoclonal - administration & dosage (22) 22
flow cytometry (22) 22
leukemia, lymphocytic, chronic, b-cell - diagnosis (22) 22
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (22) 22
pyrimidines - administration & dosage (22) 22
acute myelogenous leukemia (21) 21
antineoplastic combined chemotherapy protocols - administration & dosage (21) 21
b-cells (21) 21
neoplasm staging (21) 21
protein-tyrosine kinases - antagonists & inhibitors (21) 21
tyrosine (21) 21
antibodies, monoclonal, murine-derived (20) 20
lymphomas (20) 20
minimal residual disease (20) 20
open-label (20) 20
acute lymphoblastic-leukemia (19) 19
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Lymphoma Myeloma and Leukemia, ISSN 2152-2650, 09/2017, Volume 17, pp. S194 - S196
Journal Article
Clinical advances in hematology & oncology : H&O, ISSN 1543-0790, 04/2019, Volume 17, Issue 4, p. 214
Journal Article
Cancer Research, ISSN 0008-5472, 07/2018, Volume 78, Issue 13 Supplement, pp. 3905 - 3905
Journal Article
Leukemia & lymphoma, ISSN 1042-8194, 06/2019, pp. 1 - 4
Journal Article
Oncology Times, ISSN 0276-2234, 11/2017, Volume 39, Issue 21, pp. 1 - 17
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2016, Volume 34, Issue 31, pp. 3722 - 3723
Journal Article
Cancer Research, ISSN 0008-5472, 07/2017, Volume 77, Issue 13 Supplement, pp. 3547 - 3547
Journal Article
Cancer Research, ISSN 0008-5472, 07/2017, Volume 77, Issue 13 Supplement, pp. 4408 - 4408
Journal Article
JNCCN Journal of the National Comprehensive Cancer Network, ISSN 1540-1405, 05/2015, Volume 13, Issue 5 Suppl, pp. 662 - 665
The decision of when to start treatment for patients with chronic lymphocytic leukemia (CLL) has not markedly changed; it is triggered by parameters of active... 
Antineoplastic Agents - therapeutic use | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Practice Guidelines as Topic - standards | Humans | Disease Progression
Journal Article
Oncotarget, ISSN 1949-2553, 04/2019, Volume 10, Issue 29, pp. 2793 - 2809
The PIM1, PIM2, and PIM3 serine/threonine kinases play a role in the proliferation and survival of cancer cells. Mice lacking these three kinases were viable.... 
Journal Article
Haematologica, ISSN 0390-6078, 03/2019, p. haematol.2018.207068
The utility of PET-CT in distinguishing Richter's transformation versus chronic lymphocytic leukemia progression after ibrutinib and/or idelalisib was assessed... 
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 10, pp. 1090 - 1099
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 6, pp. 768 - 778
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2016, Volume 374, Issue 4, pp. 323 - 332
Acalabrutinib is an irreversible inhibitor of Bruton's tyrosine kinase with greater specificity for the enzyme than the first-in-class agent, ibrutinib. It had... 
B-CELL RECEPTOR | MEDICINE, GENERAL & INTERNAL | ACTIVATION | IN-VIVO | X-LINKED AGAMMAGLOBULINEMIA | IBRUTINIB | BTK | PCI-32765 | TYROSINE KINASE INHIBITOR | LYMPHOMA | OPEN-LABEL | Recurrence | Benzamides - pharmacokinetics | Humans | Middle Aged | Pyrazines - administration & dosage | Male | Antineoplastic Agents - administration & dosage | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Protein Kinase Inhibitors - adverse effects | Diarrhea - chemically induced | Dose-Response Relationship, Drug | Benzamides - administration & dosage | Antineoplastic Agents - adverse effects | Female | Antineoplastic Agents - pharmacokinetics | Benzamides - adverse effects | Headache - chemically induced | Chromosome Deletion | Protein Kinase Inhibitors - pharmacokinetics | Administration, Oral | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Agammaglobulinaemia Tyrosine Kinase | Pyrazines - pharmacokinetics | Pyrazines - adverse effects | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Protein-Tyrosine Kinases - antagonists & inhibitors | Antimitotic agents | Treatment outcome | Usage | Care and treatment | Safety and security measures | Lymphocytic leukemia | Analysis | Clinical trials | Pharmacology | Dosage and administration | Pharmacokinetics | Antineoplastic agents | Tyrosine | Headache | Pharmacodynamics | Transformation | Chronic lymphatic leukemia | Inhibitor drugs | Leukemia | Diarrhea | Chromosome deletion | Lymphatic leukemia | Kinases | Lymphoma | Bruton's tyrosine kinase | Patients | Clonal deletion | Lymphomas | Safety | Drug therapy | Lymphocytosis | Protein-tyrosine kinase | Chromosome 17 | Index Medicus | Abridged Index Medicus
Journal Article
Cancer Research, ISSN 0008-5472, 10/2014, Volume 74, Issue 19 Supplement, pp. 4769 - 4769
Journal Article
American Journal of Hematology, ISSN 0361-8609, 04/2017, Volume 92, Issue 4, pp. 405 - 406
Journal Article
Blood, ISSN 0006-4971, 01/2016, Volume 127, Issue 3, pp. 303 - 309
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2016, Volume 374, Issue 4, pp. 311 - 322
An oral inhibitor of BCL2 produces substantial responses in the majority of patients with refractory chronic lymphocytic leukemia. The agent is so effective... 
DOSE-ESCALATION | APOPTOSIS | MEDICINE, GENERAL & INTERNAL | CLL | INTERNATIONAL WORKSHOP | CYCLOPHOSPHAMIDE | RITUXIMAB | IBRUTINIB | INHIBITOR | PHASE-I | FLUDARABINE | Recurrence | Humans | Middle Aged | Male | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Antineoplastic Agents - administration & dosage | Remission Induction | Sulfonamides - pharmacokinetics | Dose-Response Relationship, Drug | Disease-Free Survival | Bridged Bicyclo Compounds, Heterocyclic - adverse effects | Tumor Lysis Syndrome - etiology | Antineoplastic Agents - adverse effects | Aged, 80 and over | Sulfonamides - adverse effects | Adult | Female | Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors | Aged | Antineoplastic Agents - pharmacokinetics | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Sulfonamides - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - pharmacokinetics | Antimitotic agents | Treatment outcome | Care and treatment | Usage | Safety and security measures | Lymphocytic leukemia | Analysis | Clinical trials | Dosage and administration | Antineoplastic agents | Pharmacokinetics | Risk factors | Flow cytometry | Chronic lymphatic leukemia | Cell survival | Leukemia | Minimal residual disease | Diarrhea | Chromosome deletion | Nausea | Lymphatic leukemia | Lymphoma | Patients | Proteins | Chemotherapy | Fludarabine | Clonal deletion | Lysis | Respiratory tract diseases | Lymphomas | Chromosome 17 | Neutropenia | Apoptosis | Index Medicus | Abridged Index Medicus
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.